TY - JOUR
T1 - Innovative financing for health
T2 - What is truly innovative?
AU - Atun, Rifat
AU - Knaul, Felicia Marie
AU - Akachi, Yoko
AU - Frenk, Julio
N1 - Funding Information:
GAVI and the Global Fund largely depend for funding on ODA, with relatively large sums received from one philanthropic institution; by contrast, UNITAID, which has benefited from strong bilateral support by the French Government in the establishment of the airlines tax, has successfully used several new sources to generate innovative financing. UNITAID has strategically targeted areas where it could best leverage its funds—eg, by substantially affecting prices of medicines and diagnostics, and by funding medicines to treat multidrug-resistant tuberculosis and antiretroviral treatment for children in programmes supported by the Global Fund.
PY - 2012/12
Y1 - 2012/12
N2 - Development assistance for health has increased every year between 2000 and 2010, particularly for HIV/AIDS, tuberculosis, and malaria, to reach US$26·66 billion in 2010. The continued global economic crisis means that increased external fi nancing from traditional donors is unlikely in the near term. Hence, new funding has to be sought from innovative fi nancing sources to sustain the gains made in global health, to achieve the health Millennium Development Goals, and to address the emerging burden from non-communicable diseases. We use the value chain approach to conceptualise innovative fi nancing. With this framework, we identify three integrated innovative fi nancing mechanisms-GAVI, Global Fund, and UNITAID-that have reached a global scale. These three fi nancing mechanisms have innovated along each step of the innovative fi nance value chain-namely resource mobilisation, pooling, channelling, resource allocation, and implementation-and integrated these steps to channel large amounts of funding rapidly to low-income and middle-income countries to address HIV/AIDS, malaria, tuberculosis, and vaccine-preventable diseases. However, resources mobilised from international innovative fi nancing sources are relatively modest compared with donor assistance from traditional sources. Instead, the real innovation has been establishment of new organisational forms as integrated fi nancing mechanisms that link elements of the fi nancing value chain to more eff ectively and effi ciently mobilise, pool, allocate, and channel fi nancial resources to low-income and middle-income countries and to create incentives to improve implementation and performance of national programmes. These mechanisms provide platforms for health funding in the future, especially as eff orts to grow innovative fi nancing have faltered. The lessons learnt from these mechanisms can be used to develop and expand innovative fi nancing from international sources to address health needs in low-income and middle-income countries.
AB - Development assistance for health has increased every year between 2000 and 2010, particularly for HIV/AIDS, tuberculosis, and malaria, to reach US$26·66 billion in 2010. The continued global economic crisis means that increased external fi nancing from traditional donors is unlikely in the near term. Hence, new funding has to be sought from innovative fi nancing sources to sustain the gains made in global health, to achieve the health Millennium Development Goals, and to address the emerging burden from non-communicable diseases. We use the value chain approach to conceptualise innovative fi nancing. With this framework, we identify three integrated innovative fi nancing mechanisms-GAVI, Global Fund, and UNITAID-that have reached a global scale. These three fi nancing mechanisms have innovated along each step of the innovative fi nance value chain-namely resource mobilisation, pooling, channelling, resource allocation, and implementation-and integrated these steps to channel large amounts of funding rapidly to low-income and middle-income countries to address HIV/AIDS, malaria, tuberculosis, and vaccine-preventable diseases. However, resources mobilised from international innovative fi nancing sources are relatively modest compared with donor assistance from traditional sources. Instead, the real innovation has been establishment of new organisational forms as integrated fi nancing mechanisms that link elements of the fi nancing value chain to more eff ectively and effi ciently mobilise, pool, allocate, and channel fi nancial resources to low-income and middle-income countries and to create incentives to improve implementation and performance of national programmes. These mechanisms provide platforms for health funding in the future, especially as eff orts to grow innovative fi nancing have faltered. The lessons learnt from these mechanisms can be used to develop and expand innovative fi nancing from international sources to address health needs in low-income and middle-income countries.
UR - http://www.scopus.com/inward/record.url?scp=84870549429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870549429&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(12)61460-3
DO - 10.1016/S0140-6736(12)61460-3
M3 - Comment/debate
C2 - 23102585
AN - SCOPUS:84870549429
VL - 380
SP - 2044
EP - 2049
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9858
ER -